Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

This data readout follows the December 2023 press release, when the company last reported positive safety and efficacy data in 17 patients treated with reni-cel in the RUBY and EdiTHAL studies (11 and six patients, respectively). Editas stated that it has now dosed more than 20 SCD patients, completed adult cohort enrollment, and opened and enrolled patients in the adolescent cohort in the Ruby study, implicating significant progress. All patients in both studies demonstrated successful neutrophil and plate ...